News Articles Tagged: China Approval

Mazdutide in China: Advancing Obesity Management with a Novel Dual Agonist

Learn about the approval and impact of Mazdutide in China, a dual GCG/GLP-1 receptor agonist for chronic weight management, and its role in addressing the country's obesity epidemic.

Mazdutide in China: A Landmark Approval for Obesity Treatment

Innovent's mazdutide, the first dual GCG/GLP-1 receptor agonist approved in China for chronic weight management, marks a significant milestone. NINGBO INNO PHARMCHEM CO.,LTD. discusses its implications.

Innovent's Mazdutide: A Landmark Approval in China for Weight Management

Discover the significance of mazdutide's approval in China for chronic weight management, a breakthrough for the first dual GCG/GLP-1 receptor agonist.